Clinical Trials Directory

Trials / Completed

CompletedNCT02982057

Non Culprit Lesion Study

A Randomized Trial of the Treatment of Non- Culprit Lesion After STEMI: Bioresorbable Vascular Scaffold Versus Optimal Medical Therapy (NCLstudy)

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The aim of the present study is to compare the evolution of non culprit lesions after treatment by BVS versus optimal medical therapy at 2-years follow- up

Detailed description

Objectives and hypothesis: scaffolding a non culprit /vulnerable coronary plaque with BVS could facilitate the stabilization process into the atherosclerotic plaque with modifications of plaque morphology, especially the lipid content which is considered as one of the main factor leading to recurrent MACE after an ACS. The interaction between the polymer Platform and the vessel wall, the effect of the everolimus on neointima growth and cellular response into the media could reduce the inflammatory process into the vulnerable plaque could be different Under OMT and BVS implantation.

Conditions

Interventions

TypeNameDescription
DEVICEthe ABSORB:bioresorbable vascular scaffold
DRUGO.M.T

Timeline

Start date
2015-01-01
Primary completion
2019-11-01
Completion
2019-11-01
First posted
2016-12-05
Last updated
2020-05-05

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT02982057. Inclusion in this directory is not an endorsement.